Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia

Table 1

Demographic and tumor characteristics of patients.

Characteristic	Number (%)
Age (years)
Median	56.0
Sex
Female	42 (42)
Male	58 (58)
ECOG PS
PS 0	8 (8)
PS 1	53 (53)
PS 2	36 (36)
PS 3	3 (3)
Histopathology type
Adenocarcinoma (NOS)	89 (89)
Mucinous adenocarcinoma	10 (10)
Signet ring adenocarcinoma	1 (1)
Site of primary cancer
Right-side	24 (24)
Left-side	76 (76)
Stage at diagnosis
I	2 (2)
II	5 (5)
III	29 (29)
IV	64 (64)
KRAS status
Wild	44 (44)
Mutant	66 (66)
Site of metastasis
Liver	51 (51)
Lung	41 (41)
Lymph nodes	32 (32)
Peritoneum	18 (18)
Number of metastatic sites
1 site	21 (21)
2 sites	33 (33)
>2 sites	46 (46)
Number of metastatic lesions
1–2 lesions	11 (11)
3–5 lesions	26 (26)
>5 lesions	63 (63)
Lines of chemotherapy and biologic agents
Oxaliplatin	100 (100)
Irinotecan	100 (100)
Capciabine	5 (5)
5FU/leucovorin	2 (2)
Regorafenib	10 (10)
Cetuximab	25 (25)
Panitumumab	3 (3)
Bevacizumab	49 (49)

ECOG PS: Eastern Cooperative Oncology Group performance status; NOS: not otherwise specified; Ad: adenocarcinoma; right-side: ascending+transverse colon; left-side, descending colon+Sigmoid+rectum.